

**AMENDMENT**

In the Specification

Immediately below the title of the invention, please insert

-- Related Applications

B1  
This application is a continuation-in-part of U.S. Ser. No. 08/643,321, filed  
May 6, 1996. --

Immediately before the ~~claims~~, please insert the enclosed Sequence Listing.

B2  
On page 8, line 10, after "human OP-1" please insert (residues 330-431 of SEQ ID  
NO:1) -- .

On page 16, line 6, please delete "SEQ ID NO:2 of U.S. Pat. No. 5,266,683" and  
substitute -- ~~SEQ ID NO: 1~~ -- therefor.

In the Claims

Please cancel claims 5 and 11, and amend claims 1-3 and 6-10 as follows:

B3  
1. (Amended) A method of treatment for a mammal in, or at risk of, chronic renal failure  
comprising

administering to said mammal a therapeutically effective amount of an OP/BMP renal  
therapeutic agent,

wherein said OP/BMP renal therapeutic agent comprises a dimeric protein having an  
amino acid sequence having at least 70% amino acid sequence homology with the C-terminal  
seven-cysteine skeleton of human OP-1, amino acids 330-431 of SEQ ID NO:1;

wherein said OP/BMP renal therapeutic agent induces chondrogenesis in an *in vivo*  
ectopic bone assay; and